Enzo Biochem To Be Acquired By Battery Ventures For Around $37 Mln

Enzo Biochem, Inc. (OTCQX: ENZB) has agreed to be acquired by Battery Ventures, through its newly formed entity Bethpage Parent, Inc., for $0.70 per share in cash, valuing the deal at approximately $37 million. This acquisition price represents a substantial premium of 75% to Enzo's April 22 closing price and 32% to its June 23 closing price. The company's Board unanimously approved the all-cash offer, citing its immediate and compelling value for shareholders. The transaction is anticipated to close in the third quarter of this calendar year, after which Enzo Biochem will become a privately held entity and its shares will be delisted.

Analysis

Enzo Biochem, Inc. (ENZB) has entered into a definitive agreement to be acquired by Battery Ventures in an all-cash transaction valued at approximately $37 million. The acquisition price of $0.70 per share represents a substantial premium for shareholders, specifically 75% over the company's closing price on April 22 and 32% over the June 23 price. According to the Chairman of the Strategic Committee, the board's unanimous approval follows a thorough strategic review, with the conclusion that this deal maximizes shareholder value by providing an immediate and compelling cash offer. The transaction, expected to close in the third quarter of the current calendar year, will result in Enzo Biochem being taken private and its shares delisted from public trading. This event provides a clear exit and a defined cash value for existing investors, effectively removing further market and operational risks associated with the company's standalone public entity.

Key Decisions for Investors

• For current Enzo Biochem shareholders, the key decision is whether to sell at the current market price to realize immediate gains or hold until the transaction closes to capture the full $0.70 per share, which involves accepting the minor risk of deal failure.
• Potential investors should recognize that any new position in ENZB is exclusively a merger arbitrage play, with a firm ceiling at the $0.70 acquisition price and a timeline contingent on the deal closing as expected in the third quarter.
• Given the company will be taken private and its shares delisted, long-term equity investors should treat this as a liquidity event and consider reallocating capital, as there will be no future opportunity to participate in the company's value creation through public markets.